First International Urology Cancer Summit
29.09.23 – Portsmouth, UK
Time zone is BST (British Summer Time)
10:00
Welcome by Chairs
Giuseppe Luigi Banna (UK) & Ravindran Kanesvaran (Singapore)
10:05
Doublet or triplet in mHSPC
Neeraj Agarwal (US)
10:25
When ARSIs and chemotherapy fail in mCRPC what next
Elena Castro (Spain)
10:45
Hypofractionated & metastases-directed radiotherapy (MDRT) in mPC
Alison Tree (UK)
11:05
Open discussion & coffee break
11:25
Theragnostics in mPCa: Diagnosis and Treatment
Gopinath Gnanasegaran (UK)
11:45
Antibody-drug conjugates and targeted therapies in UC
Simon Crabb (UK)
12:05
Today biomarkers and targets
Pasquale Rescigno (UK)
12:25
Industry Lunch Symposia
Only in presence – no CPD/CME credits
13:45
How to choose first-line therapy for mRCC
Monty Pal (USA)
14:15
When surgery should be offered in mRCC
Jeremy Teoh (Hong Kong, China)
14:35
Are prognostic scores useful for adjuvant and palliative therapy in mRCC
Sara E. Rebuzzi (Italy)
14:55
Open discussion & coffee break
15:15
Debate –Immunotherapy in adjuvant RCC and urothelial cancer – PROs
Yuksel Urun (Turkey)
15:35
Debate – Immunotherapy in adjuvant RCC and urothelial cancer – CONs
Richard Griffiths (UK)
15:55
Barriers and opportunities to evidence in the real-world – Panel discussion
Gil Morgan (Sweden)